Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell

Cytokine

Volumn 60, Issue 1, 2012, Pages 114-121

  Li, Xu ^a   Zheng, Zhen ^a   Li, Xin ^a   Ma, Xiaochun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine; Endothelial cells; Nuclear factor B; P38 mitogen activated protein kinase; Unfractionated heparin

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACTIVE TRANSPORT, CELL NUCLEUS; BLOTTING, WESTERN; CELL NUCLEUS; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; E-SELECTIN; ENDOTHELIAL CELLS; GENE EXPRESSION; HEPARIN; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MICROVESSELS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR RELA;

EID: 84865417529     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.008     Document Type: Article

References (23)

1. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256. [PubMed: 12682500].
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. [PubMed: 11445675].
3. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430. [PubMed: 16281932].
4. Schouten M., Wiersinga W.J., Levi M., et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008, 83:536-545. [PubMed:18032692].
5. Levi M., Van der Poll T., Büller H.R. Bidirectional relation between inflammation and coagulation. Circulation 2004, 109:2698-2704. [PubMed:15184294].
6. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
7. Liu S.F., Malik A.B. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290:L622-L645. [PubMed: 16531564].
8. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. [PubMed:18158437].
9. Barrow R.T., Parker E.T., Krishnaswamy S., et al. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994, 269:26796-26800. [PubMed: 7929416].
10. Tyrell D.J., Kilfeather S., Page C.P. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995, 16:198-204. [PubMed: 7652929].
11. Harada N., Okajima K., Uchiba M. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Crit Care Med 2006, 34:1883-1891. [PubMed: 16641616].
12. Morrison A.M., Wang P., Chaudry I.H. A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis. Shock 1996, 6:46-51. [PubMed: 8828084].
13. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126(3 Suppl):188S-203S.
14. Tsai P.S., Chen C.C., Tsai P.S., et al. Heme oxygenase 1, nuclear factor E2-related factor 2, and nuclear factor kappaB are involved in hemin inhibition of type 2 cationic amino acid transporter expression and l-arginine transport in stimulated macrophages. Anesthesiology 2006, 105:1201-1210.
15. Wenzel R.P. Treating sepsis. N Engl J Med 2002, 347:966-967.
16. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765-3777.
17. Matthay M.A. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001, 344:759-762.
18. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
19. Amaral A., Opal S.M., Vincent J.L. Coagulation in sepsis. Intensive Care Med 2004, 30:1032-1040.
20. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
21. Brueckmann M., Hoffmann U., Dvortsak E., et al. Drotrecogin alfa(activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004, 53(10):528-533.
22. Thourani V.H., Brar S.S., Kennedy T.P., et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000, 278:H2084-2093.
23. Manduteanu I., Voinea M., Antohe F., et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003, 477:269-276.